Press Room

Article / Nov 10, 2017

Learning From History: For CMOs the Cycle is Back

Guy Villax, November 10, 2017

What is happening to the CMO industry (particularly the pharmaceutical fine chemical industry) looks pretty similar to what it did almost 20 years ago. The attached 13 articles written between 1998 and 2005 -half of which were written by me- recount a well-known story: exuberance and over-investment results in write-offs and losses. What happened then was crystal clear to me when in 1998 someone came with a large cheque book convinced that a $500m API business could be built in 3-5 years. Shortly thereafter a well-known Deutsche Bank analyst’s report made sure the herd mentality took over. By 2005 most of the $15bn or so spent in M&A deals were mostly written off and a number of wonderful brands and several major companies had vanished.

It is interesting to note that at the time that some entered the CMO business Honeywell was exiting and said: “...pharmaceutical chemical manufacture is a highly capital intensive business plagued by over-capacity, clinical trial failures, limited new drug approvals, new drug marketing disappointments, and price wars…” 

Maybe there is an opportunity to learn from history. The challenge today is to check whether what looks the same is indeed the same, and whether what is really different can contribute to a different outcome. What remains to be seen is whether outsiders understand what they are getting into, and one thing is certain: when the dust settles you will have the usual suspects picking up the pieces.

If anything we should be concerned because as of today over $33bn have already been spent in CMO related M&A activity in the last 4 years – in exactly the same pattern as in 1995-7, 1998-2000.

Yours,
Guy

# Title  Type Author Date
1 The API Solution Provider article Guy Villax 1998
2 Aggressive goals - $500m in 3-5 years ppt Solutia 1998
3 Deutsche Bank analyst's report on CMO article DB 1999
4 Hovione in the CPHI show daily 2001 article Guy Villax 2001
5 Pharma Fine Chemicals - Nothing has changed! article Guy Villax 2002
6 Outsourcing: The dust has now settled  article Guy Villax 2002
7 European producers face unique issues article Maureen Rouhi 2005
8 Why Fine Chemical Business Development has failed  ppt Peter Pollak 2005
9 GMP fraud - largest ever penalties in criminal pharma  web www.infojustice.com 2005
10 Clients, competitors and Consultants  ppt Guy Villax 2005
11 Fine Chemicals Revisited  article Guy Villax 2005
12 5 years after its buying spree…  article Clay Boswell 2005
13 The Gold Sheet  article  Bill Paulson  2006

View the full set of documents (PDF, 8MB)

 

Guy Villax
Hovione
+351 917 888 899

Also in the Press Room

See All

Continuous Tableting (CT) is defined as continuous manufacturing of oral dose drugs, specifically tablets. As per ICH's Q13 definition1, a continuous manufacturing process in the pharmaceutical industry comprises at least two unit operations integrated from a mechanical and software perspective. There is a wide combination of possible CT process configurations that are dependent on the needs of the intended product formulation and each of the individual unit operations that constitute the process train can be continuous, semi-continuous, or batch processes. The typical manufacturing processes for tablet formulation are direct compression (DC), dry granulation (DG) and wet granulation (WG)2 - details on these manufacturing processes are beyond the scope of this article, so the interested reader is directed to relevant literature. The actual implementation of CT technology in a facility can broadly vary depending on the level of desired integration and automation. Process trains can be designed to be flexible and converted between multiple configurations (e.g. continuous DC, DG and WG), controlled by the end user from one single software and within a single clean room. The other possibility would be for subsections of the CT process to be divided into multiple clean rooms where inprocess materials are transferred between suites via a bin-to-bin approach (e.g. a granulation suite to prepare granules from raw materials followed by continuous DC (CDC) to blend the granules and produce tablets). The level of automation and instrumentation designed into the CT process (typically involving Process Analytical Technologies, PAT) can open the possibility to implement sophisticated control strategies. Key components of a control strategy that need to be considered for CT are material tracking and genealogy, knowledge of the residence time distribution (RTD), and in-process controls (spectroscopic and/or soft sensors based on process parameters). Holistically, these control strategy elements enable the implementation of a material diversion strategy to automatically divert out of specification material from the process. In their most advanced form, control strategies may also enable real time release testing (RTRt) of the final tablet drug product and reduce the off-line analytical burden and the number of operators needed to manage the process.   Read the full article at gmp-journal.com  

Article

Continuous Tableting and the Road to Global Adoption

Mar 04, 2024